1. Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study 
Ioan-Andrei Iliuta, MD MHSc, Beili Shi, MD PhD, Marina Pourafkari, MD, Pedram Akbari, MSc, Giancarlo Bruni, MD, Ralph Hsiao, Steffan F. Stella, MD, Korosh Khalili, MD, Eran Shlomovitz, MD, York Pei, MD MSc 
Kidney Medicine 
DOI: /j.xkme
Copyright © Terms and Conditions

2. Kidney Medicine DOI: (10.1016/j.xkme.2019.07.015)
Copyright © Terms and Conditions

3. Figure 1
Study flowchart. Sixty-eight consecutive patients were scheduled for foam sclerotherapy but 66 were treated and analyzed. AKI: acute kidney injury.
Kidney Medicine DOI: ( /j.xkme )
Copyright © Terms and Conditions

4. Figure 2
Changes in median kidney volume post-sclerotherapy. There was a 21.8% (249 ml) decrease in the targeted kidney volume (n=95; p<0.001) and a 3.4% increase (22 ml) in the non-targeted kidney volume (n=37; p<0.001). The mean (SD) time interval between MRI scans pre- and post-sclerotherapy was 13.6 (4.9) months.
Kidney Medicine DOI: ( /j.xkme )
Copyright © Terms and Conditions

5. Figure 3
Changes in patient-reported outcome symptoms post-sclerotherapy (n=56). Among 33, 18, and 22 patients who had flank/back pain, abdominal pain, and abdominal distension before sclerotherapy, 70% (23/33), 78% (14/18), and 59% (13/22) respectively experienced an improvement of their symptoms post-sclerotherapy. (NBS: no baseline symptoms. None, mild, moderate, and significant refer to the degree of improvement in symptoms).
Kidney Medicine DOI: ( /j.xkme )
Copyright © Terms and Conditions

6. Figure 4
Case examples illustrating improved kidney function post-sclerotherapy. (a) Successful ablation of a very large right midpole kidney cyst with improved creatinine clearance consistently up to 14 months after the procedure. (b) Successful ablation of a large right lower pole kidney cyst with improved creatinine clearance 17 months after the procedure. PT: protein-truncating; TKV: total kidney volume; CrCl: creatinine clearance; FS: foam sclerotherapy.
Kidney Medicine DOI: ( /j.xkme )
Copyright © Terms and Conditions

7. Figure 5
Case examples illustrating no change in kidney function post-sclerotherapy in potentially inadequately treated patients. PT: protein-truncating; TKV: total kidney volume; CrCl: creatinine clearance; FS: foam sclerotherapy.
Kidney Medicine DOI: ( /j.xkme )
Copyright © Terms and Conditions

8. Figure 6
Case examples illustrating no change in kidney function post-sclerotherapy associated with advanced parenchymal disease. PT: protein-truncating; TKV: total kidney volume; CrCl: creatinine clearance; FS: foam sclerotherapy.
Kidney Medicine DOI: ( /j.xkme )
Copyright © Terms and Conditions